Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Concord Drugs Ltd
Your Vote -
Buy
86.67%
Hold
0.00%
Sell
13.33%
86.67%
15 users have voted
Option Chain
Analyzes market sentiment, predicts Concord Drugs Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Concord Drugs - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Concord Drugs has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025
-
Concord Drugs - Board Meeting Outcome for Outcome Of Board Meeting
-
Concord Drugs - Board Meeting Intimation for Reschedule Of Board Meeting
-
Concord Drugs - Board Meeting Intimation for To Consider Fund Raising By Way Of Preferential Issue
Key fundamentals
Evaluate the intrinsic value of Concord Drugs Ltd stock
Name | March-24 | March-23 | March-22 | March-21 | March-20 |
---|---|---|---|---|---|
Assets | 47.8258 | 46.5061 | 44.7948 | 39.7395 | 33.0529 |
Liabilities | 47.8258 | 46.5061 | 44.7948 | 39.7395 | 33.0529 |
Equity | 10 | 9.3155 | 8.7437 | 8.7438 | 8.7438 |
Gross Profit | 3.6772 | 4.3437 | 5.5924 | 3.2198 | 3.344 |
Net Profit | 0.4194 | 0.8922 | 1.5943 | 3.2817 | 0.3283 |
Cash From Operating Activities | 1.9598 | 2.2448 | 0.7741 | 1.6157 | 2.1555 |
NPM(%) | 0.96 | 1.73 | 2.7 | 6.38 | 0.63 |
Revenue | 43.2607 | 51.3143 | 58.9564 | 51.357 | 51.3389 |
Expenses | 39.5835 | 46.9706 | 53.3639 | 48.1372 | 47.9949 |
ROE(%) | 1.23 | 2.63 | 4.7 | 9.68 | 0.96 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|
Peers
Other companies within the same industry or sector that are comparable to Concord Drugs Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Albert David Ltd | 824.20 | -1.99 | 11.65 | 17.09 | 1321.50 | 1.39 |
Lotus Eye Hospital and Institute Ltd | 80.41 | -0.74 | 338.42 | 62.28 | 14.01 | 0.62 |
Bharat Immunological and Biologicals Corporation Ltd | 23.00 | -1.41 | 0.00 | 129.32 | -39.50 | 0.00 |
Astec Lifesciences Ltd | 681.00 | -1.58 | 0.00 | 58.73 | -687.11 | 0.00 |
Company Info
Concord Drugs Limited (CDL) is incorporated as a Limited Company on 24th April 1995 with the Registrar of companies, Andhra Pradesh. The registered office of the Company is situated at Survey No. 249, Brahmanpally Village, Hayatnagar Mandal, R.R. District, Hyderabad-501511 Concord Drugs Limited was established in 1995 to manufacture and market innovative pharmaceutical products. Concord's three core product areas are generics, branded and specialty pharmaceuticals. The Company ranks among the top generics suppliers in India. Manufacturers of AMCRYLATE [ISO Amyl 2-Cyanoacrylate] a sterile tissue adhesive used in for sutureless surgeries first time in Asia in collaboration with Indian Institute of Chemical Technology [IICT], Hyderabad a premier CSIR Laboratory. The Technology Information, Forecasting and Assessment Council [TIFAC], New Delhi has helped the company to mass produce `AMCRYLATE' and bring it to Indian consumers. TIFAC was also associated in providing Techno-managerial guidance to the Company. The product is patented in India for Concord Drugs Limited. Further the Company has established Unit-II or Phase-II at Roorkee, Uttrakhand in 2005 for manufacturing of Tablets & Capsules.AMCRYLATE is non-pigmented, non-toxic, non-allergic, bacteriostatic and bio-static adhesive. It allows rapid wound closure with minimal scarring, reduces the risk of post surgical infection and trauma, besides being simple and safe to use.Also set-up a plant for Small Volume Parenterals in liquid ampoules/vials and powder Parenterals and also Tablets & Capsules with Betalactum & Non-Betalactum both sections. 2015 -Concord Drugs Ltd are listed and admitted to dealings on the Exchange in the list of 'DT' Group Securities.
Concord Drugs Limited (CDL) is incorporated as a Limited Company on 24th April 1995 with the Registrar of companies, Andhra Pradesh. The registered office of the Company is situated at Survey No. 249, Brahmanpally Village, Hayatnagar Mandal, R.R. District, Hyderabad-501511 Concord Drugs Limited was established in 1995 to manufacture and market innovative pharmaceutical products. Concord's three core product areas are generics, branded and specialty pharmaceuticals. The Company ranks among the top generics suppliers in India. Manufacturers of AMCRYLATE [ISO Amyl 2-Cyanoacrylate] a sterile tissue adhesive used in for sutureless surgeries first time in Asia in collaboration with Indian Institute of Chemical Technology [IICT], Hyderabad a premier CSIR Laboratory. The Technology Information, Forecasting and Assessment Council [TIFAC], New Delhi has helped the company to mass produce `AMCRYLATE' and bring it to Indian consumers. TIFAC was also associated in providing Techno-managerial guidance to the Company. The product is patented in India for Concord Drugs Limited. Further the Company has established Unit-II or Phase-II at Roorkee, Uttrakhand in 2005 for manufacturing of Tablets & Capsules.AMCRYLATE is non-pigmented, non-toxic, non-allergic, bacteriostatic and bio-static adhesive. It allows rapid wound closure with minimal scarring, reduces the risk of post surgical infection and trauma, besides being simple and safe to use.Also set-up a plant for Small Volume Parenterals in liquid ampoules/vials and powder Parenterals and also Tablets & Capsules with Betalactum & Non-Betalactum both sections. 2015 -Concord Drugs Ltd are listed and admitted to dealings on the Exchange in the list of 'DT' Group Securities.
Read More
Parent Organisation
Concord Drugs Ltd.
Founded
24/04/1995
Managing Director
Mr.S Nagi Reddy
NSE Symbol
FAQ
The current price of Concord Drugs Ltd is
The 52-week high for Concord Drugs Ltd is
The market capitalization of Concord Drugs Ltd is currently
This value can fluctuate based on stock price movements and changes in the number of shares outstanding.To buy Concord Drugs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Concord Drugs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Concord Drugs Ltd shares.
The CEO of Concord Drugs Ltd is Mr.S Nagi Reddy, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.